Table 1.
Summary of Published Studies of Hormonal Therapy as Adjuvant to Radical Prostatectomy
| Disease-free Survival | Overall Survival | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adjuvant | Disease | Median | Adjuvant | Adjuvant | ||||||
| Study | Therapy | n | Stage | Follow-up (y) | + RP | RP Alone | P Value | + RP | RP Alone | P Value |
| Messing et al12 | Goserelin | 98 | cT1–T2, | 10 | Data not available for 10 years* | 72% | 49% | .025 | ||
| or BO | pN1-N3 | |||||||||
| Prayer-Galetti | ||||||||||
| et al13 | Goserelin | 201 | pT3 | 5 | 25.2% difference favoring adjuvant | NA | NA | NA | ||
| Wirth et al11 | Flutamide | 365 | pT3 | 4 | 90%† | 69%† | .0029 | NA | NA | NA |
BO, bilateral orchiectomy; NA, not available; RP, radical prostatectomy.
*
Disease-free survival at 7.1 years’ follow-up was 77% for adjuvant + RP, 43% for RP alone; P<.001.14
†
Including freedom from biochemical recurrence in addition to local or systemic recurrence